Stockscreener 앱 받기
31.90
1.59%
0.50
시간 외 거래:
33.41
1.51
+4.73%
전일 마감가:
$31.40
열려 있는:
$31.33
하루 거래량:
275.03K
Relative Volume:
0.47
시가총액:
$1.65B
수익:
$447.57M
순이익/손실:
$-38.92M
주가수익비율:
-38.43
EPS:
-0.83
순현금흐름:
$-1.15M
1주 성능:
-1.27%
1개월 성능:
-2.48%
6개월 성능:
+4.56%
1년 성능:
+39.06%
1일 변동 폭
$30.98
$32.02
1주일 범위
$30.98
$33.10
52주 변동 폭
$20.20
$43.11
Atricure Inc Stock (ATRC) Company Profile
명칭
Atricure Inc
전화
513-755-4100
주소
7555 INNOVATION WAY, MASON, OH
ATRC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
31.90 | 1.65B | 447.57M | -38.92M | -1.15M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
515.09 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
169.72 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.35 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
254.52 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
216.70 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-17 | 재개 | JP Morgan | Overweight |
| 2024-04-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-23 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-29 | 개시 | UBS | Buy |
| 2021-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-12-18 | 재확인 | Needham | Buy |
| 2020-11-06 | 재확인 | Needham | Buy |
| 2020-04-07 | 개시 | Oppenheimer | Outperform |
| 2020-02-06 | 개시 | BTIG Research | Buy |
| 2020-01-24 | 재확인 | Needham | Buy |
| 2019-08-13 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | 개시 | JP Morgan | Overweight |
| 2018-10-04 | 재확인 | Needham | Buy |
| 2018-08-02 | 재확인 | Needham | Buy |
| 2018-08-02 | 재확인 | Stifel | Buy |
| 2018-06-18 | 재확인 | Needham | Buy |
| 2018-04-27 | 재확인 | Needham | Buy |
| 2018-01-16 | 재확인 | Needham | Buy |
| 2017-11-02 | 재확인 | Needham | Buy |
| 2017-07-28 | 재확인 | Needham | Buy |
| 2017-05-30 | 재개 | Piper Jaffray | Overweight |
| 2016-06-30 | 재개 | JMP Securities | Mkt Outperform |
| 2015-10-28 | 재확인 | Needham | Buy |
| 2015-10-06 | 재확인 | Canaccord Genuity | Buy |
| 2015-10-06 | 재확인 | Needham | Buy |
모두보기
Atricure Inc 주식(ATRC)의 최신 뉴스
Cryoablation Probe Market Size, Share | Industry Report 2030 - Grand View Research
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? - Yahoo Finance
Transcript : AtriCure, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener
AtriCure at Goldman Sachs Conference: Strategic Growth Insights - Investing.com India
AtriCure at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com UK
Ameriprise Financial Inc. Invests $295,000 in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
Global Cardiac Ablation Market: Advancements in Minimally Invasive Procedures and 13% CAGR by 2030 - PharmiWeb.com
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Jane Street Group LLC - Defense World
AtriCure (NASDAQ:ATRC) Downgraded to “Hold” Rating by Wall Street Zen - Defense World
(ATRC) Investment Analysis - news.stocktradersdaily.com
AtriCure’s chief scientific officer sells $83,600 in stock By Investing.com - Investing.com India
Insider Sell: Vinayak Doraiswamy Sells 2,500 Shares of AtriCure Inc (ATRC) - GuruFocus
AtriCure’s chief scientific officer sells $83,600 in stock - Investing.com Australia
Investors push AtriCure (NASDAQ:ATRC) 3.9% lower this week, company's increasing losses might be to blame - simplywall.st
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $823,000 Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure, Inc. (ATRC) Stock Analysis: Evaluating a 52.52% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Deutsche Bank AG - Defense World
AtriCure (NASDAQ:ATRC) Upgraded by Wall Street Zen to “Buy” Rating - Defense World
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference | ATRC Stock News - GuruFocus
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Yahoo Finance
Bank of America Corp DE Sells 208,694 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure Inc (ATRC) Trading 3.4% Higher on May 20 - GuruFocus
Focus Partners Wealth Acquires Shares of 16,306 AtriCure, Inc. (NASDAQ:ATRC) - Defense World
D. E. Shaw & Co. Inc. Sells 49,834 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
(ATRC) On The My Stocks Page - news.stocktradersdaily.com
AtriCure Stockholders Approve Stock Incentive Plan Amendment - TipRanks
Left Atrial Appendage Devices Market | Latest Trends, Growth, - openPR.com
AtriCure Names New COO, CFO - Medical Product Outsourcing
AtriCure Enrolls First Two Patients in DEEP Clinical Study - Medical Product Outsourcing
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect? - Yahoo Finance
Questex’s Fierce Healthcare Announces 2025 Fierce DEI Award Finalists - GlobeNewswire Inc.
When (ATRC) Moves Investors should Listen - news.stocktradersdaily.com
AtriCure Q1 2025 presentation: Revenue up 13.6%, raises full-year guidance - Investing.com
Dimensional Fund Advisors LP Purchases 136,015 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure CEO details growth trajectory toward becoming a $1B company - The Business Journals
AtriCure targets $517M-$527M revenue in 2025 with strong growth in appendage management and pain management - MSN
Left Atrial Appendage Closure Market to Set Phenomenal Growth - openPR.com
AtriCure, Inc. (NASDAQ:ATRC) Q1 2025 Earnings Call Transcript - Insider Monkey
Shareholders in AtriCure (NASDAQ:ATRC) have lost 40%, as stock drops 11% this past week - Yahoo Finance
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch - simplywall.st
Needham cuts AtriCure stock target to $44, maintains buy rating By Investing.com - Investing.com Nigeria
AtriCure price target lowered to $52 from $58 at BTIG - TipRanks
AtriCure price target lowered to $51 from $52 at Canaccord - TipRanks
AtriCure’s Strong Q1: Revenue Growth and Challenges - TipRanks
Needham cuts AtriCure stock target to $44, maintains buy rating - Investing.com Australia
UBS Adjusts AtriCure (ATRC) Price Target Amid Core Business Stre - GuruFocus
AtriCure, Inc. SEC 10-Q Report - TradingView
UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating - marketscreener.com
14 Analysts Assess AtriCure: What You Need To Know - Benzinga
AtriCure (ATRC) Target Price Revised Amid Mixed Sector Performan - GuruFocus
Atricure Inc (ATRC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
0.90%
자본화:
|
볼륨(24시간):